ASCO Guidelines
ASCO Guidelines Podcast breaks down pivotal recommendations from the latest evidence-based clinical practice guidance and provides insight into daily patient care. Listen to stay up to date with the ever-evolving landsca...
Insights from recent episode analysis
On the show
- Dr. Joshua Reuss2 eps
- Dr. Nabil Saba1 ep
- Dr. Timothy Gilligan1 ep
Also: Dr. Calvin Chou, Dr. Lakshmi Rajdev, Dr. Manish Shah, Dr. Bishal Gyawali, Dr. Tessa Cigler, Dr. Sonam Puri, Dr. Mary-Ellen Taplin, Dr. Lisa Hicks, Dr. Joseph Mikhael, Dr. Alison Loren, Dr. Ann Partridge, Dr. Tanya Thomas, Dr. Aparna Jotwani, Dr. Rahul Banerjee, Tina Lockwood, Stacy Gray, Dr. Lyudmila Bazhenova
Audience Interest
Podcast Focus
Publishing Consistency
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Based on the show's feed history.
Built from
By chart position
- 🇦🇷AR · Medicine#452.4K to 30K
- 🇦🇺Australia · Medicine#1041.8K to 22K
- 🇻🇳VN · Medicine#461.4K to 17K
- 🇳🇬NG · Medicine#481.3K to 16K
- 🇹🇭TH · Medicine#57976 to 12K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
9.6K to 118K🎙 Daily cadence·202 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
32K to 392K🇺🇸71%🇦🇷7%🇦🇺5%+8 more - Active Followers
Loyal subscribers who consistently listen
13K to 157K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/26/26 | Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update | Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on a patient's risk of recurrence, moving away from a one-size-fits-all model. They detail the recommendations for low, intermediate, and high-intensity surveillance groups, review the current role of blood-based biomarkers like ctDNA, and clarify the guideline's stance on supplemental imaging such as MRI and ultrasound. The co-chairs emphasize the importance of shared decision-making between clinicians and patients and discuss how these updated recommendations aim to improve quality of life and reduce unnecessary testing for breast cancer survivors. Read the full guideline, "Breast Cancer Follow-up and Surveillance after Primary Treatment: ASCO Guideline Update," at www.ascopubs.org/topics/asco-guidelines/breast-cancer" LINK TO FULL TRANSCRIPT | 19m 32s | ||||||
| 8/24/26 | Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0 | Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resistant or platinum-refractory disease. The discussion covers systemic therapy options, the role of maintenance therapy with agents like bevacizumab, and the nuanced recommendations for secondary cytoreductive surgery based on mixed clinical trial results. Drs. Lesnock and Bouberhan emphasize the importance of an individualized, multidisciplinary approach to care. As this is a living guideline, they also look ahead to emerging evidence that will shape future updates. Read the full living guideline, "Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0," at www.ascopubs.org/guidelines/systemic-treatment-ovarian-cancer-recurrence" LINK TO FULL TRANSCRIPT | 21m 26s | ||||||
| 7/28/26 | Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.2 | Dr. Sonam Puri joins the podcast to share the update to the living guideline on stage IV NSCLC with driver alterations. Dr. Puri discusses the practice-changing evidence reviewed for both NTRK rearrangements, including the TRIDENT-1 trial, and HER2 activating mutations, including the Beamion LUNG-1 study. She shares how these results impacted the clinical practice guideline with the addition of repotrectinib and zongertinib, what these new TKIs mean for patients, and where the panel is waiting for additional randomized data to clarify the role of therapeutic options. Dr. Puri encourages listeners to stay tuned for future updates to the living guideline as new evidence is published. Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2" at www.ascopubs.org/guidelines/therapy-stage-iv-non-small-cell-lung-cancer-driver-alterations" LINK TO FULL TRANSCRIPT | 9m 00s | ||||||
| 6/29/26 | multiple myelomatreatment guidelines+4 | Dr. Rahul Banerjee | teclistamabdaratumumab+4 | — | multiple myelomaASCO guidelines+6 | — | 17m 45s | ||
| 6/18/26 | circulating tumor DNAsolid tumors+5 | Tina LockwoodStacy Gray | American Society of Clinical OncologyCirculating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | — | ctDNAbiopsy+5 | — | 17m 31s | ||
| 5/26/26 | NSCLCdriver alterations+4 | Dr. Joshua Reuss | American Society of Clinical OncologyTherapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1 | — | NSCLCEGFR mutations+4 | — | 19m 00s | ||
| 5/26/26 | Stage IV NSCLCLiving guideline update+5 | Dr. Lyudmila Bazhenova | POD1IM-304BAP BRAIN+3 | — | NSCLCdriver alterations+7 | — | 13m 27s | ||
| 4/1/26 | thyroid cancersystemic treatment+4 | Dr. Nabil Saba | American Society of Clinical OncologyEmory University+2 | — | thyroid cancersystemic treatment+5 | — | 23m 25s | ||
| 3/10/26 | patient-clinician communicationoncology guidelines+5 | Dr. Timothy GilliganDr. Calvin Chou | American Society of Clinical OncologyJournal of Clinical Oncology+1 | — | communication skillsoncology+5 | — | 31m 22s | ||
| 2/26/26 | immunotherapytargeted therapy+4 | Dr. Lakshmi RajdevDr. Manish Shah | American Society of Clinical OncologyJournal of Clinical Oncology+2 | — | gastroesophageal adenocarcinomaesophageal squamous cell carcinoma+7 | — | 28m 55s | ||
| 2/25/26 | hematopoietic colony-stimulating factorscancer treatment+4 | Dr. Bishal GyawaliDr. Tessa Cigler | American Society of Clinical OncologyWhite Blood Cell Growth Factors: ASCO Guideline Update | — | CSFsprimary prophylaxis+7 | — | 23m 22s | ||
| 2/3/26 | NSCLCdriver alterations+4 | Dr. Sonam Puri | American Society of Clinical OncologyMoffitt Cancer Center+2 | www.asco.org/thoracic-cancer-guidelinesascopubs.org | NSCLCdriver alterations+7 | — | 19m 36s | ||
| 2/3/26 | stage IV NSCLCliving guidelines+3 | Dr. Joshua Reuss | American Society of Clinical OncologyGeorgetown University+2 | ASCO | NSCLCdriver alterations+3 | — | 18m 03s | ||
| 1/20/26 | metastatic castration-resistant prostate cancerASCO guidelines+3 | Dr. Mary-Ellen Taplin | American Society of Clinical OncologyDana-Farber Cancer Institute+2 | — | mCRPCADT+5 | — | 13m 37s | ||
| 1/6/26 | multiple myelomatreatment guidelines+4 | Dr. Lisa HicksDr. Joseph Mikhael | American Society of Clinical OncologyOntario Health+2 | — | multiple myelomatreatment options+5 | — | 22m 18s | ||
| 12/11/25 | cancer managementpregnancy+4 | Dr. Alison LorenDr. Ann Partridge | American Society of Clinical Oncology | — | cancer during pregnancyASCO guidelines+3 | — | 34m 50s | ||
| 9/18/25 | antineoplastic extravasationoncology nursing+3 | Dr. Tanya ThomasDr. Aparna Jotwani | Oncology Nursing SocietyAmerican Society of Clinical Oncology+2 | — | extravasationvesicant agents+5 | — | 13m 28s | ||
Showing 17 of 202
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for ASCO Guidelines
Peaked at #45 in AR, currently #45 in AR.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| AR | — | #45 | #45 | — |
| VN | — | #46 | #46 | — |
| NG | — | #48 | #48 | — |
| TH | — | #57 | #57 | — |
| HK | — | #80 | #80 | — |
| RO | — | #96 | #96 | — |
| Australia | — | #104 | #104 | — |
| CO | — | #119 | #119 | — |
| KE | — | #129 | #129 | — |
| TR | — | #137 | #137 | — |
| CH | — | #167 | #167 | — |
| Spain | — | #197 | #197 | — |
Chart Positions
12 placements across 12 markets.
Chart Positions
12 placements across 12 markets.